We have previously described the identification of a nucleoside analog transcriptional inhibitor ARC (4-amino-6-hydrazino-7-b-D-ribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide) that was able to induce apoptosis in cancer cell lines of different origin. Here, we report the characterization of ARC on a panel of neuroblastoma cell lines. We found that these cell lines were more than 10-fold sensitive to ARC than to the well-known nucleoside analog DRB (5,6-dichloro-1-b-Dribofuranosylbenzimidazole), and that ARC-induced apoptosis proceeds through mitochondrial injury. Also, we observed that ARC-mediated cell death was accompanied by caspase-3 cleavage and repression of antiapoptotic proteins such as Mcl-1 and survivin. Conversely, we found that overexpression of Mcl-1-protected neuroblastoma cell line NB-1691 from ARC-induced apoptosis. Furthermore, we found that while ARC inhibited the phosphorylation of Akt Ser-473 in multiple cancer cell lines, forced expression of myristoylated Akt promoted resistance to ARC-induced apoptosis in neuroblastoma cells. In addition, we observed that ARC was able to downregulate the protein levels of N-myc, a commonly amplified oncogene in neuroblastomas, and Akt protected N-myc from ARCinduced downregulation. These data suggest that ARC may antagonize different antiapoptotic pathways and induce apoptosis in neuroblastoma cells via multiple mechanisms. Overall, ARC could represent an attractive candidate for anticancer drug development against neuroblastomas.
Neuroblastoma, the most common pediatric solid tumor is associated with high morbidity and mortality, and accounts for 15% of all pediatric cancer-related deaths in the United States (Brodeur, 2003; van Noesel and Versteeg, 2004) . It is derived from primitive cells of the sympathetic nervous system and approximately 50% of all neuroblastomas arise in the adrenal medulla. Although the treatment outcome for children with advanced stage neuroblastoma has improved, 5-year event free survival in most studies is less than 30% (Castel et al., 2000 (Castel et al., , 2001 . In a few studies, survival reaching 34% has been reported in patients with N-myc amplification (>10 copies) receiving intensified regimens of cytotoxic agents (Kaneko et al., 2002) . While the survival rate is significantly higher than that from less intensive regimens, two-thirds of high-risk patients with N-myc amplification will succumb to their disease. Furthermore, the survival of patients with advanced disease without N-myc amplification (o10 copies) is not much greater (Kaneko et al., 2002) . Cytotoxic therapies (doxorubicin, cyclophosphamide, etoposide, irinotecan and cisplatin) still play a major role in neuroblastoma treatment (Furman et al., 1999; Thompson et al., 1999 Thompson et al., , 2001 Houghton and Santana, 2002; Castel and Canete, 2004; Donfrancesco et al., 2004) . Bone marrow or peripheral blood stem cell transplants appear to have some value increasing relapse-free survival, at least in some studies (Matthay et al., 1999; Valteau-Couanet et al., 2000; Imaizumi et al., 2001; Goldsby and Matthay, 2004) . Differentiation agents and immunotherapies have also been seen to increase survival in patients having a complete or good partial response during induction therapy. Despite the availability of these options, only 12-20% of children with advanced disease achieve long-term survival with conventional therapies. Thus, there is still a need to develop more effective, less toxic therapies that will boost survival probability for these children.
Nucleoside analog ARC (4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide) is a global transcriptional inhibitor, which we previously identified using a high-throughput cellbased assay (Radhakrishnan and Gartel, 2006b ). Treatment of cancer cells with ARC displayed the hallmarks of transcriptional repression such as the induction of p53, and the repression of its target genes mdm2 and p21. A striking feature of ARC was its ability to induce apoptosis in transformed and cancer, but not in normal cells, underscoring the potential usefulness of this compound in anticancer therapy. Here, to analyse the effect of ARC on neuroblastomas, we made use of NB-1691, SK-N-AS, SK-N-SH and IMR32 cell lines. We treated these cells with different concentrations of ARC (0, 3, 10 and 30 mM) for 48 h and measured cell viability using the Alamar blue method. We found that cell viability was much reduced in the treated samples when compared to the control (Figure 1a ). To quantitatively evaluate the level of sensitivity of these neuroblastoma cell lines toward ARC, we performed a growth inhibition assay on cells treated with varying concentrations of ARC (0, 0.01, 0.1, 1 and 10 mM) for 24 h. We found that the IC 50 for these cells were in the nanomolar range (Figure 1b) . For example, for three of the cell lines the IC 50 concentration was B200 nM, in contrast to studied colon (LIM1215, SW480 and SW620) and breast (MCF-7) epithelial cancer cell lines for which were grown in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA) and 1% penicillin-streptomycin at 371C in 5% CO 2 . These cells were treated with different concentrations of ARC (0, 3, 10 and 30 mM) for 48 h and cell viability was assessed using the Alamar blue method. Briefly, 4.6 Â 10 4 cells/well were seeded in 24-well Costar plates. Twenty-four hours later, the cells were treated with different concentrations of ARC. Forty-eight hours later, 50 ml of Alamar blue was added to each well. The plates were returned to the incubator for 4 h to allow reduction of Alamar blue to a red fluorescent intermediate, the concentration of which is proportional to the number of viable cells present in each well. The plates were read on a Cytoflour 2300 fluorimeter at an excitation of 530 nm and emission at 590 nm. (b) The neuroblastoma cell lines were treated with ARC for 24 h and growth inhibition was performed. Briefly, cells were seeded in antibiotic-free medium at a density of 200 000 cells/well in six-well flat-bottom tissue culture plates. After 24 h, the medium was replaced with fresh medium containing ARC at concentrations ranging from 0.01 to 10 mM. Cell number was determined after 24 h by lysing the cells and counting the nuclei. All measurements were made in triplicate. (c) NB-1691 cells were treated with DMSO, 5 mM ARC and 50 mM DRB, as indicated for 24 h and subjected to flow cytometric analysis after propidium iodide (PI) staining as described (Radhakrishnan et al., 2006) . Briefly, cells were fixed in ice-cold 70% ethanol and stored at À201C until further analysis. Equal numbers of fixed cells were then stained with PI solution (0.1% Triton X-100, 0.2 mg/ml DNase-free RNase and 0.02 mg/ml PI) made in PBS for 15 min at 371C and analysed by a flow cytometer. (d) NB-1691 and IMR32 cell lines were treated with the indicated concentrations of ARC or DRB for 24 h and immunoblotting was performed as described (Radhakrishnan et al., 2004; Gartel, 2005, 2006b ) with antibodies specific for cleaved caspase-3 (9664; Cell Signaling, Danvers, MA, USA) and b-actin (A5441; Sigma-Aldrich, St Louis, MO, USA).
the IC 50 was B2 to 4 mM (data not shown; manuscript in preparation).
The nucleoside analog DRB (5,6-dichloro-1-b-Dribofuranosylbenzimidazole) is another transcriptional inhibitor, which like ARC, targets the elongation stage of transcription by inhibiting the positive transcription elongation factor b (P-TEFb, a complex of Cdk9/cyclin T1) (Marshall and Price, 1992) . Previously, we had demonstrated that though ARC and DRB repressed transcription to a similar extent, ARC induced more potent apoptosis in a colon cancer cell line (Radhakrishnan and Gartel, 2006b) . To test if the neuroblastoma cell lines display differential sensitivities toward ARC and DRB, we first used NB-1691 cells and treated them with 5 mM of ARC or 50 mM of DRB for 24 h and compared them with dimethyl sulfoxide (DMSO)-treated control. Using propidium iodide (PI) staining followed by flow cytometry, we found that while ARCtreated cells underwent B15% apoptosis, DRB only induced B6% apoptosis, though the concentration of DRB used was 10-fold more than that of ARC ( Figure 1c) . Furthermore, we observed that ARC was able to induce the cleavage of caspase-3 in NB-1691 and IMR32 cell lines at B10-fold lower concentration than DRB (Figure 1d ). The significant difference in apoptosis, despite their similarity in the degree of transcriptional inhibition (Radhakrishnan and Gartel, 2006b) suggests that ARC may employ more than transcriptional repression to induce apoptosis in these neuroblastoma cell lines.
To investigate the mechanism of ARC-induced apoptosis in neuroblastoma cells, we decided to study if ARC causes mitochondrial injury. Permeabilization of the mitochondria, followed by cytochrome c release has previously been observed for transcriptional inhibitor flavopiridol (Newcomb et al., 2003) . For this analysis, we used neuroblastoma cell lines NB-1691 and IMR32 and treated them with either DMSO or 3 mM of ARC. Staining of the mitochondria in these cells by tetramethylrhodamine methyl ester followed by flow cytometry revealed that ARC is able to cause mitochondrial depolarization (Figure 2a ). These data suggest that ARC targets a step that is upstream of mitochondria to induce apoptosis. 
Targeting Akt in neuroblastoma cells SK Radhakrishnan et al
It is well known that the Bcl-2 family members (for example, Bcl-2, Bcl-XL and Mcl-1) protect mitochondrial integrity, thereby acting in an antiapoptotic manner (Martinou and Green, 2001) . It is possible that ARC modulates the expression of one or more of these proteins to cause mitochondrial injury. Consistent with this hypothesis, we found that Mcl-1 levels were dramatically reduced in four different neuroblastoma cell lines in response to 24-h ARC treatment (Figure 2b ). This reduction in Mcl-1 protein levels was accompanied by the appearance of cleaved caspase-3 and the repression of another antiapoptotic protein survivin (Figure 2b ). Of note, survivin levels were more drastically reduced when the cells were treated with ARC for 72 h when compared to the 24 h treatment (Figures 2b and c) . Owing to the robust reduction in Mcl-1 levels in only 24 h, we hypothesized that repression of Mcl-1 by ARC is necessary for ARC-induced apoptosis in these neuroblastoma cells. To test this hypothesis, we transiently overexpressed Mcl-1 in NB-1691 cells and compared them to cells transfected with empty vector. Ninety-six hours after treatment with 3 mM ARC, while the control cells underwent apoptosis, NB-1691 cells overexpressing Mcl-1 were relatively resistant (Figure 2d) . Also, transient overexpression of Mcl-1 in NB-1691 cells resulted in reduced cleavage of caspase-3 after ARC treatment (Figure 2e) , thereby strengthening the notion that Mcl-1 downregulation by ARC is a necessary event for ARC-mediated apoptosis.
Another survival pathway that protects mitochondrial integrity is the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway (Kennedy et al., 1999) . To see if Akt signaling is affected, we tested how ARC may modulate this pathway in NB-1691 cells. We found that the phosphorylation of Akt and its downstream target GSK3 were reduced in response to ARC treatment, while the total levels of these proteins remained the same (Figure 3a) . Also, as expected, were treated with the indicated concentrations of ARC for 24 h and the cell lysates were used for immunoblotting with antibodies specific for N-myc (OP13; Calbiochem, San Diego, CA, USA). For quantification of N-myc protein relative levels; films from immunoblotting were scanned and the density of the N-myc bands was analysed by an image analysis program (ImageJ, National Institute of Health, Bethesda, MA, USA). (e) IMR32 and NB1691 cell lines were treated with the indicated concentration of ARC and 24 h later the total RNA was extracted from the cells and quantitative real time reverse transcription (RT)-PCR was performed to determine the mRNA levels of N-myc. Briefly, total RNA was extracted by the TRIzol method (Invitrogen). cDNA was synthesized by using the SuperScript First Strand Synthesis Kit according to the manufacturer's recommendations (Invitrogen). N-myc-specific primers (sense, 5 0 -GACCACAAGGCCCTCAGTAC-3 0 ; antisense, 5 0 -GTGGATGGGAAGGCATCGTT-3 0 ) were used to measure the mRNA level. The level of the 18S rRNA (sense, 5 0 -GTCTGTGATGCCCTTAGATG-3 0 ; antisense, 5 0 -AGCTTATGACCCGCACTTAC-3 0 ) was used for the normalization of the data. Quantitative PCRs were carried out on the ABI 7900 HT system. The purity of the amplified products was determined by generating dissociation curves. A standard amplification curve was generated from the simultaneous amplification of the serial dilutions of the cDNA from the untreated control cells. Midpoints of the log phase of the amplification curves as determined by the PCR machine were used for the quantitation. (f) Cell lines NB1691 and NB1691-mAkt (which stably overexpresses mAkt) were treated with 3 mM of ARC. Twenty-four hours after treatment, the cells were harvested and the total cell lysates were used for immunoblotting to determine the protein levels of Akt, N-myc and cleaved caspase-3. transient overexpression of myristoylated Akt (mAkt) conferred protection against ARC-induced apoptosis in NB-1691 cells, as indicated by 4 0 ,6-diamidino-2-phenylindole staining and cleaved caspase-3 levels (Figures 3b  and c) . Data with two additional cell lines that overexpress myrisotylated Akt (Rat1a-mAkt and MCF7-mAkt) (Supplementary Figure 1) support the general notion that ARC targets the Akt pathway and Akt overexpression protects against ARC-induced toxicity. Together, these results indicate that ARC may also target the Akt signaling pathway to inflict mitochondrial injury and eventual apoptosis. This is in agreement with our observation that cells overexpressing Bcl-2 (a protector of mitochondrial integrity) are relatively resistant to ARC-induced apoptosis, though ARC does not modulate Bcl-2 protein levels per se (Bhat and Gartel, manuscript in preparation).
A recent study indicated that a direct consequence of inhibiting the PI3K/Akt pathway in certain neuroblastoma cell lines is the destabilization of N-myc protein (Chesler et al., 2006) . Since we found that ARC inhibits the Akt pathway in neuroblastoma cells, we decided to check if N-myc protein levels are affected. Treatment of NB-1691 and IMR32 cells with ARC for 24 h led to a dramatic decrease in N-myc levels (Figure 3d) , suggesting a positive correlation between the inhibition of the PI3K/Akt pathway and the decreased stability of Nmyc. Stable overexpression of mAkt in NB1691 made these cells resistant to ARC and protected them from N-myc downregulation (Figure 3f ). We found that suppression of N-myc mRNA and protein by 3 mM of ARC correlates between each other in NB-1691 cells (B45%) (Figures 3d and e) , but it appears that the reduction in mRNA levels per se (33%; Figure 3e ) by 1 mM of ARC cannot account for the more severe reduction in protein levels (78%; Figure 3d ) of N-myc in IMR32 cell line. These data suggest that ARC may target N-myc by both transcriptional inhibition and interference with the Akt signaling that stabilizes N-myc protein in neuroblastoma cells and the relative importance of these effects may vary from one neuroblastoma cell line to another. In addition, at this time, we cannot formally exclude the possibility that ARC could also affect the stability of N-myc mRNA.
Previously, we had characterized ARC on a number of cancer cell lines of epithelial origin (Radhakrishnan and Gartel, 2006b) . In this study, we have extended these studies on neuroblastoma cell lines and found that these cells are susceptible to ARC in nanomolar concentrations. Since ARC is a transcriptional inhibitor, it is well suited to downregulate proteins that have a short half-life. Antiapoptotic protein Mcl-1 is one such, which is repressed by ARC in neuroblastoma cell lines, thereby partly explaining the mechanism of action of ARC. This is consistent with earlier reports, which suggested a correlation between transcriptional inhibitor flavopiridol-induced apoptosis and Mcl-1 downregulation (Gojo et al., 2002; Ma et al., 2003) . Also, being a nucleoside analog, it is conceivable that ARC may affect a number of kinases. In fact, the basis of transcriptional repression by ARC is tied to its ability to inhibit CDK9 kinase (Radhakrishnan and Gartel, 2006a, b) , which plays a central role in transcriptional elongation (Janicke et al., 1998; Peng et al., 1998 ). Here, we tested if ARC could affect the well-known PI3K/Akt kinase survival pathway, and found that ARC indeed inhibited phosphorylation of Akt as well as its downstream target GSK3. Also, possibly as a consequence of the PI3K/Akt pathway inhibition, N-myc protein levels were also reduced in response to ARC treatment. This is especially significant given the fact that one-third of neuroblastoma tumors shows amplification of N-myc, which has a strong correlation with chemotherapy resistance (Norris et al., 1996; DuBois et al., 1999 ). Though it is still possible that in addition to antagonizing the prosurvival pathways indicated above, ARC-induced apoptosis may also involve as yet unrecognized events, our data provide at least a partial picture of the mechanism of action of ARC and suggest that it could be an attractive candidate for drug development against neuroblastoma tumors.
